VXRT vs. CCCC, OPT, KOD, GMDA, OCGN, JATT, GNTA, TSBX, BCAB, and CDTX
Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include C4 Therapeutics (CCCC), Opthea (OPT), Kodiak Sciences (KOD), Gamida Cell (GMDA), Ocugen (OCGN), JATT Acquisition (JATT), Genenta Science (GNTA), Turnstone Biologics (TSBX), BioAtla (BCAB), and Cidara Therapeutics (CDTX). These companies are all part of the "biological products, except diagnostic" industry.
Vaxart vs.
C4 Therapeutics (NASDAQ:CCCC) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
C4 Therapeutics presently has a consensus price target of $10.13, indicating a potential upside of 396.32%. Vaxart has a consensus price target of $2.75, indicating a potential upside of 285.59%. Given Vaxart's higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than Vaxart.
Vaxart has lower revenue, but higher earnings than C4 Therapeutics. Vaxart is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, C4 Therapeutics and C4 Therapeutics both had 1 articles in the media. Vaxart's average media sentiment score of 0.00 equaled C4 Therapeutics'average media sentiment score.
C4 Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Vaxart received 288 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 65.39% of users gave Vaxart an outperform vote while only 35.71% of users gave C4 Therapeutics an outperform vote.
Vaxart has a net margin of 0.00% compared to Vaxart's net margin of -872.34%. Vaxart's return on equity of -50.69% beat C4 Therapeutics' return on equity.
74.9% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Vaxart shares are owned by institutional investors. 8.0% of C4 Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
C4 Therapeutics beats Vaxart on 8 of the 15 factors compared between the two stocks.
Get Vaxart News Delivered to You Automatically
Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
